Eli Lilly to Acquire Houston Cancer-Fighting Startup CrossBridge Bio in $300M Deal

Eli Lilly has taken a decisive step to enhance its oncology pipeline by agreeing to acquire CrossBridge Bio, a Houston-based biotech startup specializing in cancer treatments, for $300 million. This acquisition is set to enrich Eli Lilly’s development of cutting-edge therapies, particularly those aimed at combating solid tumors that have historically been difficult to treat. CrossBridge Bio’s innovative biopharmaceutical assets, which have demonstrated promising results in preclinical studies, will complement Lilly’s existing oncology efforts.

This strategic move aligns with Eli Lilly’s vision to broaden its presence in the oncology sector and expedite the introduction of transformative cancer therapies. The key advantages anticipated from this acquisition include:

• Exclusive access to novel drug candidates targeting complex cancer mechanisms
• Synergistic enhancement of R&D capabilities through integration of CrossBridge’s proprietary technology
• Faster progression of clinical trials utilizing Eli Lilly’s extensive global infrastructure